Pharmacokinetic profile of spectinomycin in rats

Pharmazie

Volumn 68, Issue 8, 2013, Pages 675-676

  Madhura, D B ^a   Lee, R ^b   Meibohm, B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SPECTINOMYCIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CATTLE; CHICKEN; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TISSUE LEVEL; EXPERIMENTAL PIG; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SHEEP; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; SPECTINOMYCIN;

EID: 84883230605     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.3501     Document Type: Article

References (11)

1. Abu-Basha EA, Gehring R, Albwa'neh SJ (2007) Pharmacokinetics and bioavailability of spectinomycin after i.v., i.m., s.c. and oral administration in broiler chickens. J Vet Pharmacol Ther 30: 139-144. (Pubitemid 46365034)
2. Cuerpo L, Livingston RC (1994) Spectinomycin. In: Residues of some veterinary drugs in animals and foods monograph, 42nd meeting of the joint FAO/WHO expert committee on food additives, FAO Food Nutr Pap 41: 1-86.
3. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095. (Pubitemid 23211439)
4. Davies J, Anderson P, Davis BD (1965) Inhibition of protein synthesis by spectinomycin. Science 149 (3688): 1096-1098.
5. De Broe ME (1999) Renal injury due to environmental toxins, drugs, and contrast agents. In: Berl T, Bonventre JV (ed.) Atlas of Diseases of the Kidney, Volume 1, p. 11.1-11.6.
6. Ellis RL, LivingstonRC(1994) Spectinomycin. In: Addendum to the Spectinomycin residue mongraph, 42nd meeting of the Committee, FAO Food and Nutr Pap 41: 119-132.
7. Mingeot-Leclercq MP, Piret J, Brasseur R, Tulkens PM (1990) Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition by aminoglycoside antibiotics-I: Biochemical analysis, Biochem Pharmacol 40: 489-497. (Pubitemid 20241112)
8. Novak E, Paxton LM, Bye A, Patel R, Zurenko GE, Francom SF (1990) Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F). Antimicrob Agents Chemother 34: 2342-2347.
9. Ward KW, Smith BR (2004) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. clearance. Drug Metab Dispos 32: 603-611. (Pubitemid 38668152)
10. Ziv G, Sulman FG (1973) Serum and milk concentrations of spectinomycin and tylosin in cows and ewes. Am J Vet Res 34: 329-333.
11. Zurenko GE, Yagi BH, Vavra JJ,Wentworth BB (1988) In vitro antibacterial activity of strospectomycin a novel spectinomycin analog (U-63366F). Antimicrob Agents Chemother 32: 216-223. (Pubitemid 18061378)